公开(公告)号：EP4438734A2

公开(公告)日：2024-10-02

申请号：EP24181335.1

申请日：2011-06-14

申请人： The Scripps Research Institute

发明人： KIM, Janghwan ,  ZHU, Saiyong ,  HILCOVE, Simon ,  DING, Sheng ,  EFE, Jem

IPC分类号： C12N15/85

CPC分类号： C12N5/0657 ,  C12N2501/15520130101 ,  C12N2501/60220130101 ,  C12N2501/60320130101 ,  C12N2501/60420130101 ,  C12N2501/60620130101 ,  C12N2506/130720130101 ,  C12N2510/0020130101 ,  C12N5/0618 ,  C12N2501/72720130101 ,  C12N5/0678 ,  C12N2501/0120130101 ,  C12N5/0676 ,  C12N5/0623

摘要： The present invention generally provides methods and compositions for transdifferentiation of an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate. Also provided are methods and compositions for the transdifferentiation of an animal cell from a non-pluripotent mesodermal, endodermal, or ectodermal cell fate to a different non-pluripotent mesodermal, endodermal, or ectodermal cell fate.

公开(公告)号：EP4433574A1

公开(公告)日：2024-09-25

申请号：EP22894054.0

申请日：2022-11-17

申请人： The Governing Council of the University of Toronto

发明人： CALLAGHAN, Neal I ,  SIMMONS, Craig A.

IPC分类号： C12N5/077 ,  C12N5/00 ,  C12N5/02

CPC分类号： C12N5/0657 ,  C12N2506/4520130101 ,  C12N2500/4620130101 ,  C12N2501/23520130101 ,  C12N2501/10520130101 ,  C12N2500/2520130101 ,  C12N2501/3920130101

公开(公告)号：EP4400164A2

公开(公告)日：2024-07-17

申请号：EP23171073.2

申请日：2016-10-27

申请人： Yeda Research and Development Co. Ltd

发明人： TZAHOR, Eldad ,  BASSAT, Elad

IPC分类号： A61P9/00

CPC分类号： A61K38/1709 ,  A61L27/54 ,  C12N5/0657 ,  A61L2300/25220130101 ,  C12N2501/99820130101 ,  A61P9/10

摘要： The invention relates to a method of inducing proliferation of cardiomyocytes, the method comprising contacting the cardiomyocytes with an effective amount of an Agrin peptide which induces proliferation of the cardiomyocytes, wherein said agrin peptide is 80-110 kDa and is not a part of a fusion polypeptide.

公开(公告)号：EP3402543A1

公开(公告)日：2018-11-21

申请号：EP17738878.2

申请日：2017-01-11

申请人： Cedars-Sinai Medical Center

发明人： MARBAN, Eduardo ,  GALLET, Romain

IPC分类号： A61L27/38 ,  A61K35/34

CPC分类号： A61K35/34 ,  C12N5/0657

摘要： Heart failure with preserved ejection fraction (HFpEF) is a disease condition characterized by heart failure (HF) signs and symptoms, but with normal or near normal left ventricular ejection fraction (LVEF) and is not responsive to standard therapy for treatment of HF. Described herein are compositions and methods related to use of cardiosphere derived cells (CDCs) and their exosomes to improve left ventricular structure, function and overall outcome. Administration of CDCs led to improved LV relaxation, lower LV end-diastolic pressure, decreased lung congestion and enhanced survival. Lower risk of arrhythmias in HFpEF was also observed following CDC administration. Improvement of diastolic dysfunction following administration of CDC-derived exosomes was observed, along with decreased mortality. In view of these salutary effects, CDCs and CDC-derived exosomes are beneficial in the treatment of HFpEF.

公开(公告)号：EP2582792B1

公开(公告)日：2018-10-31

申请号：EP11796584.8

申请日：2011-06-20

申请人： FUJIFILM Cellular Dynamics, Inc.

发明人： MEYER, Nathan ,  SWANSON, Brad ,  FIENE, Steve

IPC分类号： C12N5/071 ,  C12N5/02

CPC分类号： C12N5/0657 ,  C12N2500/00 ,  C12N2501/999

摘要： Methods and composition for maintenance of cardiomyocytes are provided. For example, in certain aspects methods including culturing the cardiomyocytes in a medium essentially free of serum or containing dialyzed serum to maintain long-term purity. In further aspects, methods for modulation of cardiomyocytes may be provided.

公开(公告)号：EP3344758A1

公开(公告)日：2018-07-11

申请号：EP16767044.7

申请日：2016-08-31

申请人： Pluriomics B.v.

发明人： BRAAM, Stefan Robbert ,  GRANDELA, Ana Catarina Martins

IPC分类号： C12N5/077

CPC分类号： C12N5/0657 ,  C12N2500/25 ,  C12N2501/105 ,  C12N2501/415 ,  C12N2506/45

摘要： The current invention relates to a method of differentiation of human pluripotent stem cells into a human stem-cell derived population of cardiomyocytes. The method comprises the use of specific combination of steps and compounds to induce and/or promote differentiation. The method also comprises steps directed to further maturation of the cardiomyocytes obtained with the method of the invention. Also provided are kits for use in a method of differentiation as well as cell populations obtainable with the method disclosed.

公开(公告)号：EP3259346A4

公开(公告)日：2018-07-11

申请号：EP16753173

申请日：2016-02-19

申请人： BAYLOR COLLEGE MEDICINE

发明人： PATEL VIVEKKUMAR B ,  WANG HONGRAN ,  SINGH VIVEK P ,  REINEKE ERIN LYNN ,  MATHISON MEGUMI ,  COONEY AUSTIN J ,  ROSENGART TODD

IPC分类号： C12N5/071 ,  A61K9/00 ,  A61K31/47 ,  A61K31/713 ,  A61K38/17 ,  A61K48/00 ,  C07K14/47 ,  C07K14/82 ,  C12N5/00 ,  C12N5/077 ,  C12N15/00 ,  C12N15/113 ,  C12N15/86

CPC分类号： C12N15/113 ,  A61K9/0019 ,  A61K31/47 ,  A61K31/713 ,  A61K38/1709 ,  A61K48/0058 ,  C07K14/4702 ,  C07K14/4746 ,  C07K14/82 ,  C12N5/0657 ,  C12N15/1135 ,  C12N15/86 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/31 ,  C12N2501/60 ,  C12N2710/10043 ,  C12N2740/15043

摘要： Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.

公开(公告)号：EP3337892A2

公开(公告)日：2018-06-27

申请号：EP16766111.5

申请日：2016-08-17

申请人： Boston Scientific Scimed Inc.

发明人： HERBST, Thomas J. ,  STOLEN, Craig

IPC分类号： C12N5/077

CPC分类号： A61N1/326 ,  A61N1/056 ,  A61N1/0573 ,  A61N1/205 ,  C12N5/0657

摘要： A method for producing cardiomyocyte cells including implanting a substrate within a heart such that a first portion of the substrate is in physical contact with an endocardium and a second portion of the substrate is not in contact with the endocardium, maintaining the first portion of the substrate in contact with the endocardium for a time at least sufficient to form trabecular fibers extending between the endocardium and the second portion of the substrate, cutting away the trabecular fibers from the endocardium, cutting away the trabecular fibers from the substrate, and removing the trabecular fibers from the heart, wherein the trabecular fibers include cardiomyocyte cells.

公开(公告)号：EP2714709B1

公开(公告)日：2018-04-18

申请号：EP12790042.1

申请日：2012-05-29

申请人： University of Washington

发明人： REGNIER, Michael ,  LAFLAMME, Michael ,  MURRY, Charles ,  KORTE, F., Steven ,  LUNDY, Scott ,  HAUSCHKA, Stephen, Denison ,  CHAMBERLAIN, Jeffrey, S. ,  ODOM, Guy

IPC分类号： C12N15/86 ,  C12N9/02 ,  A61K48/00 ,  A61P9/00 ,  C07H21/04 ,  C12P21/04

CPC分类号： C12N5/0657 ,  A01K67/0275 ,  A01K2217/052 ,  A01K2227/105 ,  A01K2267/0375 ,  A61K9/0019 ,  A61K35/34 ,  A61K48/005 ,  C07K14/4716 ,  C12N7/00 ,  C12N9/0093 ,  C12N15/8509 ,  C12N15/86 ,  C12N2750/14132 ,  C12N2750/14143 ,  C12N2799/022 ,  C12N2799/025 ,  C12Y117/04001 ,  C12Y117/04002

摘要： Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.

公开(公告)号：EP3168297A4

公开(公告)日：2018-03-07

申请号：EP15819754

申请日：2015-01-05

申请人： METCELA INC

发明人： MATSUURA KATSUHISA ,  IWAMIYA TAKAHIRO

IPC分类号： C12N5/077 ,  A61K35/33 ,  A61K38/17 ,  C12N1/00 ,  C12N5/10

CPC分类号： A61K35/33 ,  A61F2/24 ,  A61K38/1774 ,  C12N1/00 ,  C12N5/0656 ,  C12N5/0657 ,  C12N5/10 ,  C12N2501/58 ,  C12N2502/1329

摘要： The purpose of the present invention is to provide a cardiac cell culture material which specifically acts on cardiac cells. In addition, another purpose of the present invention is to provide artificial organ material obtained by culturing by using said cardiac cell culture material, and a method for producing the same. Thus, provided is a cardiac cell culture, wherein functional cardiac tissue is favorably built by using a cardiac cell culture material containing VCAM-1.